Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS

Guo, Wancheng; Zhan, Anne; Mery, David E.; Munshi, Manit N.; Makhoul, Oussama; Baily, Clyde; Zangari, Maurizio; Tricot, Guido; Peng, Hongling; Shaughnessy, John D.

doi:10.1182/bloodadvances.2023011096

Cited by 5 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar single-center studies have also evaluated the performance of R2-ISS in cohorts from China and Japan [ 11 , 12 ]. An analysis in the United States has validated R2-ISS, but this was in a transplanted cohort, different from our analysis, which was predominantly in a non-transplant cohort [ 13 ].…”

mentioning

confidence: 73%

Performance of newer myeloma staging systems in a contemporary, large patient cohort

Mohyuddin,

Rubinstein,

Kumar

et al. 2024

Blood Cancer J.

View full text Add to dashboard Cite

mentioning

confidence: 73%

Performance of newer myeloma staging systems in a contemporary, large patient cohort

Mohyuddin,

Rubinstein,

Kumar

et al. 2024

Blood Cancer J.

View full text Add to dashboard Cite

“… 111 These observations showed that R2-ISS is a reliable prognostic tool for MM patients who received standard anti-myeloma treatment and upfront auto-HSCT. 112 …”

Section: Mutational Landscape Of MMmentioning

confidence: 99%

Recent Advances in the Definition of the Molecular Alterations Occurring in Multiple Myeloma

Testa,

Pelosi,

Castelli

et al. 2024

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

Multiple myeloma (MM) is a disorder of the monoclonal plasma cells and is the second most common hematologic malignancy. MM initiation and progression are dependent upon complex genomic abnormalities. The current pathogenic model of MM includes two types of primary events, represented by chromosome translocations or chromosome number alterations resulting in hyperdiploidy. These primary molecular events are observed both in MM and in monoclonal gammopathy, its premalignant precursor. Subsequent genetic events allow the progression of monoclonal gammopathy to MM and, together with primary events, contribute to the genetic complexity and heterogeneity of MM. Newer therapies have considerably improved patient outcomes; however, MM remains an incurable disease and most patients experience multiple relapses. The dramatic progresses achieved in the analysis of the heterogeneous molecular features of different MM patients allowed a comprehensive molecular classification of MM and the definition of an individualized prognostic model to predict an individual MM patient’s response to different therapeutic options. Despite these progresses, prognostic models fail to identify a significant proportion of patients destined to early relapse. Treatment strategies are increasingly. Based on disease biology, trials are enriched for high-risk MMs, whose careful definition and categorization requires DNA sequencing studies. Keywords: Multiple Myeloma; Chromosome Abnormalities; Molecular Events; Mutations.

show abstract

R2-ISS staging combined with circulating plasma cells improves risk stratification for newly diagnosed multiple myeloma: a single-center real-world study

Chu,

Wang,

Gao

et al. 2024

Ann Hematol

View full text Add to dashboard Cite

We aimed to evaluate if circulating plasma cells (CPC) detected by flow cytometry could add prognostic value of R2-ISS staging. We collected the electronic medical records of 336 newly diagnosed MM patients (NDMM) in our hospital from January 2017 to June 2023. The median overall survival (OS) for patients and R2-ISS stage I-IV were not reached (NR), NR, 58 months and 53 months, respectively. There was no significant difference in OS between patients with stage I and patients with stage II (P = 0.309) or between patients with stage III and patients with stage IV (P = 0.391). All the cases were re-classified according to R2-ISS stage and CPC numbers ≥ 0.05% (CPC high) or<0.05% (CPC low) into four new risk groups: Group 1: R2-ISS stage I + R2-ISS stage II and CPC low, Group 2: R2-ISS stage II and CPC high + R2-ISS stage III and CPC low, Group 3: R2-ISS stage III and CPC high + R2-ISS stage IV and CPC low, Group 4: R2-ISS stage IV and CPC high. The median OS were NR, NR, 57 months and 32 months. OS of Group 1 was significantly longer than that of Group 2 (P = 0.033). OS in Group 2 was significantly longer than that of Group 3 (P = 0.007). OS in Group 3 was significantly longer than that of Group 4 (P = 0.041). R2-ISS staging combined with CPC can improve risk stratification for NDMM patients.

show abstract

Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS

Cited by 5 publications

References 34 publications

Performance of newer myeloma staging systems in a contemporary, large patient cohort

Performance of newer myeloma staging systems in a contemporary, large patient cohort

Recent Advances in the Definition of the Molecular Alterations Occurring in Multiple Myeloma

R2-ISS staging combined with circulating plasma cells improves risk stratification for newly diagnosed multiple myeloma: a single-center real-world study

Contact Info

Product

Resources

About